Medicare locks skin-substitute prices to 2023 data, blocks cost-based coverage denials
S. 2561 — Skin Substitute Access and Payment Reform Act of 2025 · Filed by Bill Cassidy (R-LA) · 2 cosponsors · Introduced Jul 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reforms how Medicare pays for skin substitute products—advanced biological treatments for chronic wounds like diabetic ulcers. Starting January 1, 2026, instead of paying different amounts for different products, Medicare will pay a single volume-weighted average price based on 2023 billing data, adjusted annually for inflation. The bill also consolidates all skin substitutes into one billing code and prevents Medicare from denying coverage based solely on clinical evidence, requiring manufacturers to prove only safety (contamination, infection, serious adverse reactions), not comparative effectiveness.
Why we flagged it
The bill's core mechanism is standardizing Medicare reimbursement for skin substitutes via volume-weighted averaging, but it simultaneously restricts CMS's ability to differentiate products based on clinical evidence—a constraint that appears designed to protect manufacturers from comparative-effectiveness denials rather than to serve patient interests.
What the text implies
- By locking the payment baseline to Q4 2023 data and adjusting only for CPI, the bill prevents Medicare from repricing based on new clinical evidence, market competition, or cost-effectiveness studies—effectively freezing relative product valuations for years.
- The prohibition on denying coverage 'based solely on analysis of any clinical evidence' may prevent Medicare from withdrawing coverage for products later found to be inferior or unsafe, creating a one-way ratchet favoring incumbent manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
skin substitute product manufacturers; advanced wound-care companies; biological therapy producers